Skip to main content
Fig. 5 | BMC Health Services Research

Fig. 5

From: Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Fig. 5

Cost-effectiveness acceptability curve of probabilistic sensitivity analysis: This graph presents the probability of being the optimal option at a given cost-effectiveness threshold compared to all alternative treatments in combination with methotrexate. The dashed line represents the ceiling threshold for cost-effective health technology in Thailand. ETA: Etanercept (Enbrel®), IFX: Infliximab (Remicade®), GOL: Golimumab (Simponi®), TCZ: Tocilizumab (Actemra®), RTX: Rituximab (Mabthera®), TOF: Tofacitinib (Xeljanz®), BAR: Baricitinib (Olumiant®), bsIFXr: Biosimilar infliximab (Remsima®), bsIFXi: Biosimilar infliximab (Ixifi®), bsADA: Biosimilar adalimumab (Amgevita®), bsRTX: Biosimilar rituximab (Truxima®)

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us